M&A / Deals

Degron adds $40M to series A, supporting immunology plans for molecular glue platform

BioSpace

Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-media

Immunology & Inflammation

Read full story

pharminent May 14, 2026 (Last updated: May 14, 2026)

BioSpace

Immunology & Inflammation

Read full story

Related Stories

Zydus to acquire Assertio in $166m deal

Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B

BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

You May Have Missed

Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism

With new data, Regenxbio to seek FDA approval of Duchenne gene therapy

Biotech leaders pitch Pazdur as next FDA chief

Degron adds $40M to series A, supporting immunology plans for molecular glue platform